## SUBSTITUTE FOR SENATE BILL NO. 1241

A bill to amend 1956 PA 218, entitled "The insurance code of 1956,"
(MCL 500.100 to 500.8302) by adding section 3406q.

## THE PEOPLE OF THE STATE OF MICHIGAN ENACT:

- 1 SEC. 3406Q. (1) AN EXPENSE-INCURRED HOSPITAL, MEDICAL, OR
- 2 SURGICAL POLICY OR CERTIFICATE DELIVERED, ISSUED FOR DELIVERY, OR
- 3 RENEWED IN THIS STATE THAT PROVIDES PHARMACEUTICAL COVERAGE AND A
- 4 HEALTH MAINTENANCE ORGANIZATION CONTRACT SHALL PROVIDE COVERAGE
- 5 FOR AN OFF-LABEL USE OF A FEDERAL FOOD AND DRUG ADMINISTRATION
- 6 APPROVED DRUG AND THE REASONABLE COST OF SUPPLIES MEDICALLY NEC-
- 7 ESSARY TO ADMINISTER THE DRUG.
- 8 (2) COVERAGE FOR A DRUG UNDER SUBSECTION (1) APPLIES IF ALL
- 9 OF THE FOLLOWING CONDITIONS ARE MET:
- 10 (A) THE DRUG IS APPROVED BY THE FEDERAL FOOD AND DRUG
- **11** ADMINISTRATION.

S04908'01 (S-1)

DKH

Senate Bill No. 1241 as amended May 22, 2002

- 1 (B) THE DRUG IS PRESCRIBED BY AN ALLOPATHIC OR OSTEOPATHIC
- 2 PHYSICIAN FOR THE TREATMENT OF EITHER OF THE FOLLOWING:
- 3 (i) A LIFE-THREATENING CONDITION SO LONG AS THE DRUG IS MEDICALLY NECESSARY TO TREAT THAT CONDITION AND THE DRUG IS ON THE PLAN FORMULARY OR ACCESSIBLE THROUGH THE HEALTH PLAN'S FORMULARY PROCEDURES.
- 4 (ii) A CHRONIC AND SERIOUSLY DEBILITATING CONDITION SO LONG
- 5 AS THE DRUG IS MEDICALLY NECESSARY TO TREAT THAT CONDITION AND
- 6 THE DRUG IS ON THE PLAN FORMULARY OR ACCESSIBLE THROUGH THE
- 7 HEALTH PLAN'S FORMULARY PROCEDURES.
- 8 (C) THE DRUG HAS BEEN RECOGNIZED FOR TREATMENT FOR THE CON-
- 9 DITION FOR WHICH IT IS PRESCRIBED BY 1 OF THE FOLLOWING:
- 10 (i) THE AMERICAN MEDICAL ASSOCIATION DRUG EVALUATIONS.
- 11 (ii) THE AMERICAN HOSPITAL FORMULARY SERVICE DRUG
- 12 INFORMATION.
- 13 (iii) THE UNITED STATES PHARMACOPOEIA DISPENSING INFORMA-
- 14 TION, VOLUME 1, "DRUG INFORMATION FOR THE HEALTH CARE
- 15 PROFESSIONAL".
- 16 (iv) TWO ARTICLES FROM MAJOR PEER-REVIEWED MEDICAL JOURNALS
- 17 THAT PRESENT DATA SUPPORTING THE PROPOSED OFF-LABEL USE OR USES
- 18 AS GENERALLY SAFE AND EFFECTIVE UNLESS THERE IS CLEAR AND CON-
- 19 VINCING CONTRADICTORY EVIDENCE PRESENTED IN A MAJOR PEER-REVIEWED
- 20 MEDICAL JOURNAL.
- 21 (3) UPON REOUEST, THE PRESCRIBING ALLOPATHIC OR OSTEOPATHIC
- 22 PHYSICIAN SHALL SUPPLY TO THE INSURER OR HEALTH MAINTENANCE
- 23 ORGANIZATION DOCUMENTATION SUPPORTING COMPLIANCE WITH
- 24 SUBSECTION (2).
- 25 (4) THIS SECTION DOES NOT PROHIBIT THE USE OF A COPAYMENT, DEDUCTIBLE, SANCTION.
- 26 OR A MECHANISM FOR APPROPRIATELY CONTROLLING THE UTILIZATION OF A
- 27 DRUG THAT IS PRESCRIBED FOR A USE DIFFERENT FROM THE USE FOR

S04908'01 (S-1)

## SB 1241, As Passed Senate, May 22, 2002

Senate Bill No. 1241 as amended May 22, 20020

- WHICH THE DRUG HAS BEEN APPROVED BY THE FOOD AND DRUG 1
- ADMINISTRATION. THIS MAY INCLUDE PRIOR APPROVAL OR A DRUG UTILI-2
- ZATION REVIEW PROGRAM. ANY COPAYMENT, DEDUCTIBLE, SANCTION, PRIOR 3 APPROVAL, DRUG UTIL-
- IZATION REVIEW PROGRAM, OR MECHANISM DESCRIBED IN THIS SUBSECTION 4
- SHALL NOT BE MORE RESTRICTIVE THAN FOR PRESCRIPTION COVERAGE 5
- GENERALLY. 6
- 7 (5) AS USED IN THIS SECTION:
- 8 (A) "CHRONIC AND SERIOUSLY DEBILITATING" MEANS A DISEASE OR
- 9 CONDITION THAT REQUIRES ONGOING TREATMENT TO MAINTAIN REMISSION
- OR PREVENT DETERIORATION AND THAT CAUSES SIGNIFICANT LONG-TERM 10
- 11 MORBIDITY.
- (B) "LIFE-THREATENING" MEANS A DISEASE OR CONDITION WHERE 12
- 13 THE LIKELIHOOD OF DEATH IS HIGH UNLESS THE COURSE OF THE DISEASE
- 14 IS INTERRUPTED OR THAT HAS A POTENTIALLY FATAL OUTCOME WHERE THE
- 15 END POINT OF CLINICAL INTERVENTION IS SURVIVAL.
- (C) "OFF-LABEL" MEANS THE USE OF A DRUG FOR CLINICAL INDICA-16
- TIONS OTHER THAN THOSE STATED IN THE LABELING APPROVED BY THE 17
- 18

FEDERAL FOOD AND DRUG ADMINISTRATION.

Enacting section 1. This amendatory act takes effect 180 days after the date this amendatory act is enacted.